NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MacroGenics, Inc. (MGNX) Stock Analysis

MacroGenics, Inc. (MGNX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MGNX

$4.40

+$0.15 (+3.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MGNX with… →

MGNX Key Statistics

As of Sep 4, 2026
Trading
Open
$4.20
Previous Close
$4.25
Day's Range
4.18–4.49
52-Week Range
1.29–5.08
Volume
442.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.23
Valuation
Market Cap
$280.28M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.60
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.59
Financials (FY)
Revenue (FY)
$149.50M−0.31%
Net Income (FY)
−$74.62M
Profit marginThe share of revenue left as profit after all costs and taxes.
−8.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.70M
1-Year Return
+126.80%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
860.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MGNX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+173.29%
2025−50.46%
2024−66.22%
2023+43.37%
2022−58.19%
2021−29.79%
2020+110.11%
2019−14.33%
2018−33.16%
2017−7.05%
2016 (partial year)−33.25%

As of September 4, 2026.

MGNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$149.50M−$74.62M−49.9%
2024$149.96M−$66.97M−44.7%
2023$58.75M−$9.06M−15.4%
2022$150.02M−$119.76M−79.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$149.50M$113.49M−$72.84M−$74.62M−49.9%
2024$149.96M$137.66M−$110.58M−$66.97M−44.7%
2023$58.75M$50.53M−$168.24M−$9.06M−15.4%
2022$150.02M$142.63M−$121.42M−$119.76M−79.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MGNX Valuation vs Biotechnology Median

Median of 656 stocks
MetricMGNXBiotechnology medianvs median
P/S ratio1.6015.260.1x the median
Profit margin−8.33%0.00%8.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MacroGenics, Inc. (MGNX) carries a market capitalisation of $280.28M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 293.

The most recent close on file for MGNX is $4.40, dated September 4, 2026. That is +$0.15 (+3.53%) against the previous close. Over the past 52 weeks the price has ranged from $1.29 to $5.08. The latest close sits 241.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $149.50M. That is −0.31% against the prior fiscal year, when revenue was $149.96M. The same year closed with a net loss of $74.62M. The reported profit margin is −8.33%. That is 8.3 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.59.

Across the 4 fiscal years on file, revenue moves from $150.02M in 2022 to $149.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.6 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.23. Daily returns over the trailing 10 years annualize to a volatility of 115.85%. The trailing one-year price return is +126.80%. Across 10 years the annualized return works out at −17.37%.

Growth & Income

No dividend is on file for MGNX.

So far in 2026 the price is +173.29%. The strongest complete calendar year on file is 2020 at +110.11%; the weakest is 2024 at −66.22%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

MacroGenics, Inc. (MGNX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MacroGenics, Inc. MGNX $280.28M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MacroGenics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MacroGenics, Inc.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Visit website →